<DOC>
	<DOCNO>NCT01017679</DOCNO>
	<brief_summary>This multi-center phase II randomize control study ass efficacy Gefitinib 500mg patient IIIB/IV stag non-small cell lung cancer ( NSCLC ) stable disease month treatment 250mg Gefitinib DCR , also PFS OS.The side effect evaluate well .</brief_summary>
	<brief_title>Gefitinib 500mg Versus 250mg Patients With NSCLC With Stable Disease After Month Treatment Gefitinib 250mg</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . Histologically cytologically confirm stage IIIB/IV lung cancer ( exclude patient confirm sputum cytology ) 2. receive least one chemotherapy regimen 3. stable disease month treatment gefitinib ( CT scan ) 4. radiotherapy focus measurable disease within 4 weeks.the patient receive palliative therapy include . 5 . Age &gt; 18 year , either sex 6. measurable disease ( long diameter &gt; =10mm Spiral compute tomography ( CT ) &gt; =20mm conventional CT ) least accord RECIST Criteria 7. WHO performance status ( PS ) &lt; = 2 ( Patients Whit PS=2 Should get worsen within 2 week Before Included ) 8 . N &gt; =1.5×109/L , Plt &gt; =1.5×109/L , Hb &gt; =10g/dL 9 . ALP &lt; 2.5×ULN.If ALP &gt; =2.5ULN , AST &amp; ALT &lt; 1.5ULN ( without liver metastasis ) &lt; 5ULN ( liver metastasis ) .TBIL &lt; =1.5ULN，AST &amp; ALT &lt; 2.5ULN ( without liver metastasis ) &lt; 5ULN ( liver metastasis ) . 10 . Signed date informed consent start specific protocol procedure . 11. recruit receive treatment 5 day last CT scan 12 . Patients able take oral drug 1 . Life expectancy &lt; = 12 weeks.Patients metastatic brain tumor without symptom treat include . 2. experience AntiEGFR ( epidermal growth factor receptor ) Monoclonal Antibody small molecular compound therapy erlotinib Cetuximab . 3. take drug orally , active peptic ulcer , half upper gastrointestinal dyspepsia . 4. allergic gefitinib 5 . Prior exposure drug without approval research study drug within 21days 1st day take Gefitinib 500mg 250mg . 6 . Pregnant breastfeed woman 7 . Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease . 8 . Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , basal cell carcinoma within 5 year prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>